AVBP — ArriVent Biopharma Income Statement
0.000.00%
Last trade - 00:00- $854.11m
- $553.85m
- 26
- 22
- 36
- 16
Annual income statement for ArriVent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 51.6 | 36.9 | 74.6 | 94.3 |
| Operating Profit | -51.6 | -36.9 | -74.6 | -94.3 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -51.6 | -36.9 | -69.3 | -80.5 |
| Net Income After Taxes | -51.6 | -36.9 | -69.3 | -80.5 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -51.6 | -36.9 | -69.3 | -80.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -51.6 | -36.9 | -69.3 | -80.5 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.272 | -1.15 | -2.17 | -2.56 |
| Dividends per Share |